Boston Scientific’s $1 Billion Debt Offering

Simpson Thacher represented the underwriters, led by Barclays Capital Inc., Citigroup Global Markets Inc., and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in connection with the public offering by Boston Scientific Corporation (“Boston Scientific”) of $1 billion of 4% senior notes due 2028.

Boston Scientific will use the net proceeds to redeem outstanding senior notes and repay short term debt.

Boston Scientific, as a global medical technology leader for more than 35 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. The company, led by Michael F Mahoney, Daniel J Brennan and Ian Meredith, in 2017 recorded $9.048 Billion Revenues.

The Simpson Thacher team for the transaction included Roxane Reardon (Picture) and Davis Mahon (Capital Markets); Jonathan Cantor and Jodi Schneider (Tax); Noah Leibowitz, Marcela Robledo, Katherine Helm and Amber Harezlak (Intellectual Property); Michael Isby and Timothy Mulvihill (Environmental); Jeanne Annarumma and Alina Grinman (ECEB); and Jennie Getsin (FINRA/Blue Sky).

 

Involved fees earner: Roxane Reardon – Simpson Thacher & Bartlett; Davis Mahon – Simpson Thacher & Bartlett; Jonathan Cantor – Simpson Thacher & Bartlett; Jodi Schneider – Simpson Thacher & Bartlett; Noah Leibowitz – Simpson Thacher & Bartlett; Marcela Robledo – Simpson Thacher & Bartlett; Katherine Helm – Simpson Thacher & Bartlett; Amber Harezlak – Simpson Thacher & Bartlett; Michael Isby – Simpson Thacher & Bartlett; Timothy Mulvihill – Simpson Thacher & Bartlett; Jeanne Annarumma – Simpson Thacher & Bartlett; Alina Grinman – Simpson Thacher & Bartlett; Jennie Getsin – Simpson Thacher & Bartlett;

Law Firms: Simpson Thacher & Bartlett;

Clients: Barclays Capital; Citigroup Global Markets Ltd; Merrill Lynch, Pierce, Fenner & Smith Incorporated;

 

Avatar

Author: Ambrogio Visconti